Frontiers in Oncology (Feb 2023)

Prognostic significance of ING3 expression in patients with cancer: A systematic review and meta-analysis

  • Zehan Li,
  • Shengchao Xu,
  • Lin Chen,
  • Shuqi Huang,
  • Xieyida Kuerban,
  • Tianyu Li

DOI
https://doi.org/10.3389/fonc.2023.1090860
Journal volume & issue
Vol. 13

Abstract

Read online

BackgroundIt has been reported that ING3 inhibits the progression of various cancers. However, some studies have shown that it promotes the development of prostate cancer. The purpose of this study was to investigate whether ING3 expression is associated with the prognosis of patients with cancer.Materials and methodsPubMed, Cochrane Database, Embase, Medline, ScienceDirect, Scopus and Web of Science were searched until September 2022. The hazard ratio (HR)/odds ratio (OR) and 95% confidence interval (95% CI) were calculated using Stata 17 software. We used the Newcastle-Ottawa Scale (NOS) to assess the risk of bias.ResultSeven studies involving 2371 patients with five types of cancer were included. The results showed that high expression of ING3 was negatively associated with a more advanced TNM stage (III-IV vs. I-II) (OR=0.61, 95% CI: 0.43-0.86), lymph node metastasis (OR=0.67, 95% CI: 0.49-0.90) and disease-free survival (HR=0.63, 95% CI: 0.37-0.88). However, ING3 expression was not associated with overall survival (HR=0.77, 95% CI: 0.41-1.12), tumor size (OR=0.67, 95% CI: 0.33-1.37), tumor differentiation (OR=0.86, 95% CI: 0.36-2.09) and gender (OR=1.14, 95% CI: 0.78-1.66).ConclusionThis study showed that the expression of ING3 was associated with better prognosis, suggesting that ING3 may be a potential biomarker for cancer prognosis.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier (CRD42022306354).

Keywords